EASI-SWITCH HARP-2 logo

Trial Acronym EASI-SWITCH
Clinical Area Cancer
Description Interventional study comparing whether early switch to oral antibiotics 12-24 hours after intravenous antibiotic treatment commences in patients with low risk of neutropenic sepsis is non-inferior to standard care. This is a randomised, controlled, non-inferiority trial with allocation concealment. Both arms of the trial will be conducted in parallel.
Status Open to recruitment
RECRUITMENT
Recruitment duration 1st January 2016 – 1st January 2019 (dependant on internal pilot)
Target Recruitment 628
Recruitment to date 104
TRIAL DESIGN
Trial Design A multi-centre, interventional, randomised, controlled, non-inferiority trial with allocation concealment.
Study Aim To establish the clinical and cost-effectiveness of early switch to oral antibiotics, 12-24 hours after intravenous antibiotic treatment commences in low risk cancer patients with neutropenic sepsis.
CHIEF INVESTIGATOR (CI)
Chief Investigator Dr Victoria Coyle & Dr Ronan McMullan
SPONSOR(s) & FUNDER(s)
Sponsor Belfast Health and Social Care Trust
Funder National Institute for Health Research